文献速递放疗物理与技术姑息放疗与转移瘤

重新审视放射肿瘤学中衡量成功的替代指标

Measure What Matters: Rethinking Surrogate Metrics of Success in Radiation Oncology.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2026-05-20

该研究回顾分析某NCI指定癌症中心FY15–FY24十年运营与财务数据,发现以在治患者数、分割数等传统计数替代指标与收入关联弱或呈负相关,而新治疗启动数是最可靠的价值替代指标。作者建议以新治疗启动数作为基准评估科室绩效与资源配置。

要点

  • 传统计数替代指标与收入关联弱或呈负相关,已不能反映当代放疗价值。
  • 新治疗启动数与收入强相关(r=0.90,R²=0.82),是最可靠替代指标。
  • 立体定向疗程占比从FY15的4%升至FY24的22%,分割模式显著变化。

核心结论

  • 基于计数的传统指标不再反映当代放疗的运营与财务价值。
  • 新治疗启动数是最可靠的替代指标,可同时反映临床吞吐量、财务绩效与医生工作量。
  • 以新治疗启动数为基准进行对标,可能改善绩效评估并与价值医疗对齐。

研究设计与样本

  • 单中心回顾性分析,覆盖FY15至FY24共10年。
  • 数据来自某NCI指定癌症中心的电子病历与计费系统。
  • 提取会诊、治疗启动、总分割数、每患者分割数与年度收入等指标。
  • 采用描述性统计分析运营替代指标与财务结局之间的关联。

主要发现

  • 会诊量增加77.8%,治疗启动增加43.6%,每患者平均分割数下降12.0%。
  • 立体定向疗程从FY15的39例(4%)增至FY24的291例(22%)。
  • IMRT平均疗程长度从24.6次降至13.8次。
  • 会诊至新治疗启动的转换率从92%降至71%。
  • 每患者分割数与收入呈弱或负相关(r=-0.42),收入与会诊强相关(r=0.97)但回归斜率较小(每例会诊7238美元)。

关键数值与推荐

  • 新治疗启动与收入相关r=0.90、R²=0.82,回归斜率为每例启动15500美元。
  • 专业工作相对价值单位与收入强相关,但与临床活动的一致性不均,反映其对编码结构的敏感性。

临床怎么用

  • 科室绩效评估可优先采用新治疗启动数作为价值替代指标。
  • 资源分配与对标应以新治疗启动数为基准,而非在治患者数或分割数。
  • 关注会诊至治疗启动转换率下降对运营与财务的影响。

局限性

  • 单中心回顾性研究,结果外推需谨慎。
  • 仅采用描述性统计,未报告多变量校正或因果推断。
  • 数据来自单一NCI指定癌症中心,未涉及其他机构验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Census-based surrogates such as patients on treatment, fractions delivered, and course length have traditionally been used to assess radiation oncology departmental performance. These measures may no longer capture the complexities of modern radiation therapy, given the increased adoption of hypofractionation and stereotactic techniques. This study analyzes longitudinal trends in clinical operations, including treatment modalities, fractionation patterns, and financial performance, to identify value-based departmental performance metrics. METHODS AND MATERIALS: A retrospective analysis was conducted at an (National Cancer Institute) NCI-designated cancer center spanning a 10-year period (FY15-24). Operational and financial data were extracted from electronic medical records and billing systems, including consultations, treatment starts, total fractions, fractions per patient, and annual collections. Descriptive statistics were used to assess associations between respective operational surrogates and financial outcome. RESULTS: Consultations increased by 77.8%, treatment starts by 43.6%, and average fractions per patient decreased by 12.0%. Utilization of advanced modalities (intensity modulated radiation therapy, stereotactic body radiation therapy, (stereotactic radiosurgery) SRS) grew substantially, with stereotactic courses rising from 39 courses in FY15 (4%) to 291 courses by FY24 (22%). Mean IMRT course length decreased from 24.6 to 13.8 fractions. Conversion rate from consultations to new treatment starts dropped from 92% to 71%. Fractions per patient (r = -0.42) and other census-based surrogates demonstrated weak or inverse associations with collections. Collections were strongly correlated with consultations (r = 0.97) but demonstrated a comparatively weaker regression slope ($7238/consult) compared with new treatment starts (r = 0.90, R2 = 0.82, 15,500/start). Professional work relative value units also demonstrated strong correlations with collections but showed heterogenous alignment with clinical activity, reflecting sensitivity to coding structure rather than discrete care delivery. CONCLUSIONS: Legacy tabulation-based metrics no longer reflect operational and financial value in the contemporary era. New treatment starts represent the most reliable surrogate, capturing clinical throughput, financial performance, and physician workload. Benchmarking based on new treatment initiation may improve performance assessment and appropriate resource allocation in alignment with value-based care.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Satish L, Asper J, Bonnen M, et al. Measure What Matters: Rethinking Surrogate Metrics of Success in Radiation Oncology. Int J Radiat Oncol Biol Phys. 2026. PMID: 42167702. doi:10.1016/j.ijrobp.2026.05.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。